{"id":20719,"date":"2026-11-12T10:00:44","date_gmt":"2026-11-12T09:00:44","guid":{"rendered":"https:\/\/infraviacapital.com\/?p=20719"},"modified":"2026-11-12T09:14:40","modified_gmt":"2026-11-12T08:14:40","slug":"infravia-growth-investi-dans-orakl-oncology-pour-predire-la-reponse-aux-traitements-anticancereux-avant-les-essais-cliniques","status":"publish","type":"post","link":"https:\/\/infraviacapital.com\/fr\/infravia-growth-investi-dans-orakl-oncology-pour-predire-la-reponse-aux-traitements-anticancereux-avant-les-essais-cliniques\/","title":{"rendered":"InfraVia Growth investi dans Orakl Oncology pour pr\u00e9dire la r\u00e9ponse aux traitements anticanc\u00e9reux avant les essais cliniques"},"content":{"rendered":"[vc_row type=\u00a0\u00bbin_container\u00a0\u00bb full_screen_row_position=\u00a0\u00bbmiddle\u00a0\u00bb column_margin=\u00a0\u00bbdefault\u00a0\u00bb column_direction=\u00a0\u00bbdefault\u00a0\u00bb column_direction_tablet=\u00a0\u00bbdefault\u00a0\u00bb column_direction_phone=\u00a0\u00bbdefault\u00a0\u00bb scene_position=\u00a0\u00bbcenter\u00a0\u00bb text_color=\u00a0\u00bbdark\u00a0\u00bb text_align=\u00a0\u00bbleft\u00a0\u00bb row_border_radius=\u00a0\u00bbnone\u00a0\u00bb row_border_radius_applies=\u00a0\u00bbbg\u00a0\u00bb row_position_desktop=\u00a0\u00bbdefault\u00a0\u00bb row_position_tablet=\u00a0\u00bbinherit\u00a0\u00bb row_position_phone=\u00a0\u00bbinherit\u00a0\u00bb overflow=\u00a0\u00bbvisible\u00a0\u00bb overlay_strength=\u00a0\u00bb0.3&Prime; gradient_direction=\u00a0\u00bbleft_to_right\u00a0\u00bb shape_divider_position=\u00a0\u00bbbottom\u00a0\u00bb bg_image_animation=\u00a0\u00bbnone\u00a0\u00bb shape_type=\u00a0\u00bb\u00a0\u00bb][vc_column column_padding=\u00a0\u00bbno-extra-padding\u00a0\u00bb column_padding_tablet=\u00a0\u00bbinherit\u00a0\u00bb column_padding_phone=\u00a0\u00bbinherit\u00a0\u00bb column_padding_position=\u00a0\u00bball\u00a0\u00bb flex_gap_desktop=\u00a0\u00bb10px\u00a0\u00bb column_element_direction_desktop=\u00a0\u00bbdefault\u00a0\u00bb column_element_spacing=\u00a0\u00bbdefault\u00a0\u00bb desktop_text_alignment=\u00a0\u00bbdefault\u00a0\u00bb tablet_text_alignment=\u00a0\u00bbdefault\u00a0\u00bb phone_text_alignment=\u00a0\u00bbdefault\u00a0\u00bb background_color_opacity=\u00a0\u00bb1&Prime; background_hover_color_opacity=\u00a0\u00bb1&Prime; column_backdrop_filter=\u00a0\u00bbnone\u00a0\u00bb column_shadow=\u00a0\u00bbnone\u00a0\u00bb column_border_radius=\u00a0\u00bbnone\u00a0\u00bb column_link_target=\u00a0\u00bb_self\u00a0\u00bb column_position=\u00a0\u00bbdefault\u00a0\u00bb max_width_alignment_desktop=\u00a0\u00bbdefault\u00a0\u00bb max_width_alignment_tablet=\u00a0\u00bbinherit\u00a0\u00bb max_width_alignment_phone=\u00a0\u00bbinherit\u00a0\u00bb gradient_direction=\u00a0\u00bbleft_to_right\u00a0\u00bb overlay_strength=\u00a0\u00bb0.3&Prime; width=\u00a0\u00bb1\/1&Prime; tablet_width_inherit=\u00a0\u00bbdefault\u00a0\u00bb animation_type=\u00a0\u00bbdefault\u00a0\u00bb bg_image_animation=\u00a0\u00bbnone\u00a0\u00bb border_type=\u00a0\u00bbsimple\u00a0\u00bb column_border_width=\u00a0\u00bbnone\u00a0\u00bb column_border_style=\u00a0\u00bbsolid\u00a0\u00bb][vc_row_inner column_margin=\u00a0\u00bbdefault\u00a0\u00bb column_direction=\u00a0\u00bbdefault\u00a0\u00bb column_direction_tablet=\u00a0\u00bbdefault\u00a0\u00bb column_direction_phone=\u00a0\u00bbdefault\u00a0\u00bb top_padding=\u00a0\u00bb10%\u00a0\u00bb text_align=\u00a0\u00bbleft\u00a0\u00bb row_position=\u00a0\u00bbdefault\u00a0\u00bb row_position_tablet=\u00a0\u00bbinherit\u00a0\u00bb row_position_phone=\u00a0\u00bbinherit\u00a0\u00bb overflow=\u00a0\u00bbvisible\u00a0\u00bb pointer_events=\u00a0\u00bball\u00a0\u00bb][vc_column_inner column_padding=\u00a0\u00bbno-extra-padding\u00a0\u00bb column_padding_tablet=\u00a0\u00bbinherit\u00a0\u00bb column_padding_phone=\u00a0\u00bbinherit\u00a0\u00bb column_padding_position=\u00a0\u00bbleft-right\u00a0\u00bb flex_gap_desktop=\u00a0\u00bb10px\u00a0\u00bb column_element_direction_desktop=\u00a0\u00bbdefault\u00a0\u00bb column_element_spacing=\u00a0\u00bbdefault\u00a0\u00bb desktop_text_alignment=\u00a0\u00bbdefault\u00a0\u00bb tablet_text_alignment=\u00a0\u00bbdefault\u00a0\u00bb phone_text_alignment=\u00a0\u00bbdefault\u00a0\u00bb background_color_opacity=\u00a0\u00bb1&Prime; background_hover_color_opacity=\u00a0\u00bb1&Prime; column_backdrop_filter=\u00a0\u00bbnone\u00a0\u00bb column_shadow=\u00a0\u00bbnone\u00a0\u00bb column_border_radius=\u00a0\u00bbnone\u00a0\u00bb column_link_target=\u00a0\u00bb_self\u00a0\u00bb overflow=\u00a0\u00bbvisible\u00a0\u00bb gradient_direction=\u00a0\u00bbleft_to_right\u00a0\u00bb overlay_strength=\u00a0\u00bb0.3&Prime; width=\u00a0\u00bb1\/3&Prime; tablet_width_inherit=\u00a0\u00bbdefault\u00a0\u00bb animation_type=\u00a0\u00bbdefault\u00a0\u00bb bg_image_animation=\u00a0\u00bbnone\u00a0\u00bb border_type=\u00a0\u00bbsimple\u00a0\u00bb column_border_width=\u00a0\u00bbnone\u00a0\u00bb column_border_style=\u00a0\u00bbsolid\u00a0\u00bb][vc_column_text el_class=\u00a0\u00bbbeige\u00a0\u00bb]\n<p style=\"text-align: left;\">12 novembre 2026\n[\/vc_column_text][\/vc_column_inner][vc_column_inner column_padding=\u00a0\u00bbno-extra-padding\u00a0\u00bb column_padding_tablet=\u00a0\u00bbinherit\u00a0\u00bb column_padding_phone=\u00a0\u00bbinherit\u00a0\u00bb column_padding_position=\u00a0\u00bball\u00a0\u00bb flex_gap_desktop=\u00a0\u00bb10px\u00a0\u00bb column_element_direction_desktop=\u00a0\u00bbdefault\u00a0\u00bb column_element_spacing=\u00a0\u00bbdefault\u00a0\u00bb desktop_text_alignment=\u00a0\u00bbdefault\u00a0\u00bb tablet_text_alignment=\u00a0\u00bbdefault\u00a0\u00bb phone_text_alignment=\u00a0\u00bbdefault\u00a0\u00bb background_color_opacity=\u00a0\u00bb1&Prime; background_hover_color_opacity=\u00a0\u00bb1&Prime; column_backdrop_filter=\u00a0\u00bbnone\u00a0\u00bb column_shadow=\u00a0\u00bbnone\u00a0\u00bb column_border_radius=\u00a0\u00bbnone\u00a0\u00bb column_link_target=\u00a0\u00bb_self\u00a0\u00bb overflow=\u00a0\u00bbvisible\u00a0\u00bb gradient_direction=\u00a0\u00bbleft_to_right\u00a0\u00bb overlay_strength=\u00a0\u00bb0.3&Prime; width=\u00a0\u00bb1\/3&Prime; tablet_width_inherit=\u00a0\u00bbdefault\u00a0\u00bb animation_type=\u00a0\u00bbdefault\u00a0\u00bb bg_image_animation=\u00a0\u00bbnone\u00a0\u00bb border_type=\u00a0\u00bbsimple\u00a0\u00bb column_border_width=\u00a0\u00bbnone\u00a0\u00bb column_border_style=\u00a0\u00bbsolid\u00a0\u00bb][\/vc_column_inner][vc_column_inner column_padding=\u00a0\u00bbno-extra-padding\u00a0\u00bb column_padding_tablet=\u00a0\u00bbinherit\u00a0\u00bb column_padding_phone=\u00a0\u00bbinherit\u00a0\u00bb column_padding_position=\u00a0\u00bball\u00a0\u00bb flex_gap_desktop=\u00a0\u00bb10px\u00a0\u00bb column_element_direction_desktop=\u00a0\u00bbdefault\u00a0\u00bb column_element_spacing=\u00a0\u00bbdefault\u00a0\u00bb desktop_text_alignment=\u00a0\u00bbdefault\u00a0\u00bb tablet_text_alignment=\u00a0\u00bbdefault\u00a0\u00bb phone_text_alignment=\u00a0\u00bbdefault\u00a0\u00bb background_color_opacity=\u00a0\u00bb1&Prime; background_hover_color_opacity=\u00a0\u00bb1&Prime; column_backdrop_filter=\u00a0\u00bbnone\u00a0\u00bb column_shadow=\u00a0\u00bbnone\u00a0\u00bb column_border_radius=\u00a0\u00bbnone\u00a0\u00bb column_link_target=\u00a0\u00bb_self\u00a0\u00bb overflow=\u00a0\u00bbvisible\u00a0\u00bb gradient_direction=\u00a0\u00bbleft_to_right\u00a0\u00bb overlay_strength=\u00a0\u00bb0.3&Prime; width=\u00a0\u00bb1\/3&Prime; tablet_width_inherit=\u00a0\u00bbdefault\u00a0\u00bb animation_type=\u00a0\u00bbdefault\u00a0\u00bb bg_image_animation=\u00a0\u00bbnone\u00a0\u00bb border_type=\u00a0\u00bbsimple\u00a0\u00bb column_border_width=\u00a0\u00bbnone\u00a0\u00bb column_border_style=\u00a0\u00bbsolid\u00a0\u00bb][\/vc_column_inner][\/vc_row_inner][\/vc_column][\/vc_row][vc_row type=\u00a0\u00bbin_container\u00a0\u00bb full_screen_row_position=\u00a0\u00bbmiddle\u00a0\u00bb column_margin=\u00a0\u00bbdefault\u00a0\u00bb column_direction=\u00a0\u00bbdefault\u00a0\u00bb column_direction_tablet=\u00a0\u00bbdefault\u00a0\u00bb column_direction_phone=\u00a0\u00bbdefault\u00a0\u00bb scene_position=\u00a0\u00bbcenter\u00a0\u00bb text_color=\u00a0\u00bbdark\u00a0\u00bb text_align=\u00a0\u00bbleft\u00a0\u00bb row_border_radius=\u00a0\u00bbnone\u00a0\u00bb row_border_radius_applies=\u00a0\u00bbbg\u00a0\u00bb row_position_desktop=\u00a0\u00bbdefault\u00a0\u00bb row_position_tablet=\u00a0\u00bbinherit\u00a0\u00bb row_position_phone=\u00a0\u00bbinherit\u00a0\u00bb overflow=\u00a0\u00bbvisible\u00a0\u00bb overlay_strength=\u00a0\u00bb0.3&Prime; gradient_direction=\u00a0\u00bbleft_to_right\u00a0\u00bb shape_divider_position=\u00a0\u00bbbottom\u00a0\u00bb bg_image_animation=\u00a0\u00bbnone\u00a0\u00bb][vc_column column_padding=\u00a0\u00bbno-extra-padding\u00a0\u00bb column_padding_tablet=\u00a0\u00bbinherit\u00a0\u00bb column_padding_phone=\u00a0\u00bbinherit\u00a0\u00bb column_padding_position=\u00a0\u00bball\u00a0\u00bb flex_gap_desktop=\u00a0\u00bb10px\u00a0\u00bb column_element_direction_desktop=\u00a0\u00bbdefault\u00a0\u00bb column_element_spacing=\u00a0\u00bbdefault\u00a0\u00bb desktop_text_alignment=\u00a0\u00bbdefault\u00a0\u00bb tablet_text_alignment=\u00a0\u00bbdefault\u00a0\u00bb phone_text_alignment=\u00a0\u00bbdefault\u00a0\u00bb background_color_opacity=\u00a0\u00bb1&Prime; background_hover_color_opacity=\u00a0\u00bb1&Prime; column_backdrop_filter=\u00a0\u00bbnone\u00a0\u00bb column_shadow=\u00a0\u00bbnone\u00a0\u00bb column_border_radius=\u00a0\u00bbnone\u00a0\u00bb column_link_target=\u00a0\u00bb_self\u00a0\u00bb column_position=\u00a0\u00bbdefault\u00a0\u00bb max_width_alignment_desktop=\u00a0\u00bbdefault\u00a0\u00bb max_width_alignment_tablet=\u00a0\u00bbinherit\u00a0\u00bb max_width_alignment_phone=\u00a0\u00bbinherit\u00a0\u00bb gradient_direction=\u00a0\u00bbleft_to_right\u00a0\u00bb overlay_strength=\u00a0\u00bb0.3&Prime; width=\u00a0\u00bb1\/1&Prime; tablet_width_inherit=\u00a0\u00bbdefault\u00a0\u00bb animation_type=\u00a0\u00bbdefault\u00a0\u00bb bg_image_animation=\u00a0\u00bbnone\u00a0\u00bb border_type=\u00a0\u00bbsimple\u00a0\u00bb column_border_width=\u00a0\u00bbnone\u00a0\u00bb column_border_style=\u00a0\u00bbsolid\u00a0\u00bb][vc_row_inner column_margin=\u00a0\u00bbdefault\u00a0\u00bb column_direction=\u00a0\u00bbdefault\u00a0\u00bb column_direction_tablet=\u00a0\u00bbdefault\u00a0\u00bb column_direction_phone=\u00a0\u00bbdefault\u00a0\u00bb text_align=\u00a0\u00bbleft\u00a0\u00bb row_position=\u00a0\u00bbdefault\u00a0\u00bb row_position_tablet=\u00a0\u00bbinherit\u00a0\u00bb row_position_phone=\u00a0\u00bbinherit\u00a0\u00bb overflow=\u00a0\u00bbvisible\u00a0\u00bb pointer_events=\u00a0\u00bball\u00a0\u00bb][vc_column_inner column_padding=\u00a0\u00bbpadding-2-percent\u00a0\u00bb column_padding_tablet=\u00a0\u00bbinherit\u00a0\u00bb column_padding_phone=\u00a0\u00bbinherit\u00a0\u00bb column_padding_position=\u00a0\u00bbleft-right\u00a0\u00bb flex_gap_desktop=\u00a0\u00bb10px\u00a0\u00bb column_element_direction_desktop=\u00a0\u00bbdefault\u00a0\u00bb column_element_spacing=\u00a0\u00bbdefault\u00a0\u00bb desktop_text_alignment=\u00a0\u00bbdefault\u00a0\u00bb tablet_text_alignment=\u00a0\u00bbdefault\u00a0\u00bb phone_text_alignment=\u00a0\u00bbdefault\u00a0\u00bb background_color_opacity=\u00a0\u00bb1&Prime; background_hover_color_opacity=\u00a0\u00bb1&Prime; column_backdrop_filter=\u00a0\u00bbnone\u00a0\u00bb column_shadow=\u00a0\u00bbnone\u00a0\u00bb column_border_radius=\u00a0\u00bbnone\u00a0\u00bb column_link_target=\u00a0\u00bb_self\u00a0\u00bb overflow=\u00a0\u00bbvisible\u00a0\u00bb gradient_direction=\u00a0\u00bbleft_to_right\u00a0\u00bb overlay_strength=\u00a0\u00bb0.3&Prime; width=\u00a0\u00bb2\/3&Prime; tablet_width_inherit=\u00a0\u00bbdefault\u00a0\u00bb animation_type=\u00a0\u00bbdefault\u00a0\u00bb bg_image_animation=\u00a0\u00bbnone\u00a0\u00bb border_type=\u00a0\u00bbadvanced\u00a0\u00bb border_left_desktop=\u00a0\u00bb1&Prime; column_border_color=\u00a0\u00bb#00afcd\u00a0\u00bb column_border_style=\u00a0\u00bbsolid\u00a0\u00bb][vc_column_text css_animation=\u00a0\u00bbfadeIn\u00a0\u00bb text_direction=\u00a0\u00bbdefault\u00a0\u00bb]\n<h1>InfraVia Growth investi dans Orakl Oncology pour pr\u00e9dire la r\u00e9ponse aux traitements anticanc\u00e9reux avant les essais cliniques<\/h1>\n[\/vc_column_text][\/vc_column_inner][vc_column_inner column_padding=\u00a0\u00bbno-extra-padding\u00a0\u00bb column_padding_tablet=\u00a0\u00bbinherit\u00a0\u00bb column_padding_phone=\u00a0\u00bbinherit\u00a0\u00bb column_padding_position=\u00a0\u00bball\u00a0\u00bb flex_gap_desktop=\u00a0\u00bb10px\u00a0\u00bb column_element_direction_desktop=\u00a0\u00bbdefault\u00a0\u00bb column_element_spacing=\u00a0\u00bbdefault\u00a0\u00bb desktop_text_alignment=\u00a0\u00bbdefault\u00a0\u00bb tablet_text_alignment=\u00a0\u00bbdefault\u00a0\u00bb phone_text_alignment=\u00a0\u00bbdefault\u00a0\u00bb background_color_opacity=\u00a0\u00bb1&Prime; background_hover_color_opacity=\u00a0\u00bb1&Prime; column_backdrop_filter=\u00a0\u00bbnone\u00a0\u00bb column_shadow=\u00a0\u00bbnone\u00a0\u00bb column_border_radius=\u00a0\u00bbnone\u00a0\u00bb column_link_target=\u00a0\u00bb_self\u00a0\u00bb overflow=\u00a0\u00bbvisible\u00a0\u00bb gradient_direction=\u00a0\u00bbleft_to_right\u00a0\u00bb overlay_strength=\u00a0\u00bb0.3&Prime; width=\u00a0\u00bb1\/3&Prime; tablet_width_inherit=\u00a0\u00bbdefault\u00a0\u00bb animation_type=\u00a0\u00bbdefault\u00a0\u00bb bg_image_animation=\u00a0\u00bbnone\u00a0\u00bb border_type=\u00a0\u00bbsimple\u00a0\u00bb column_border_width=\u00a0\u00bbnone\u00a0\u00bb column_border_style=\u00a0\u00bbsolid\u00a0\u00bb][\/vc_column_inner][\/vc_row_inner][\/vc_column][\/vc_row][vc_row type=\u00a0\u00bbin_container\u00a0\u00bb full_screen_row_position=\u00a0\u00bbmiddle\u00a0\u00bb column_margin=\u00a0\u00bb50px\u00a0\u00bb column_direction=\u00a0\u00bbdefault\u00a0\u00bb column_direction_tablet=\u00a0\u00bbdefault\u00a0\u00bb column_direction_phone=\u00a0\u00bbdefault\u00a0\u00bb scene_position=\u00a0\u00bbcenter\u00a0\u00bb top_padding=\u00a0\u00bb3%\u00a0\u00bb text_color=\u00a0\u00bbdark\u00a0\u00bb text_align=\u00a0\u00bbleft\u00a0\u00bb row_border_radius=\u00a0\u00bbnone\u00a0\u00bb row_border_radius_applies=\u00a0\u00bbbg\u00a0\u00bb row_position_desktop=\u00a0\u00bbdefault\u00a0\u00bb row_position_tablet=\u00a0\u00bbinherit\u00a0\u00bb row_position_phone=\u00a0\u00bbinherit\u00a0\u00bb overflow=\u00a0\u00bbvisible\u00a0\u00bb overlay_strength=\u00a0\u00bb0.3&Prime; gradient_direction=\u00a0\u00bbleft_to_right\u00a0\u00bb shape_divider_position=\u00a0\u00bbbottom\u00a0\u00bb bg_image_animation=\u00a0\u00bbnone\u00a0\u00bb gradient_type=\u00a0\u00bbdefault\u00a0\u00bb shape_type=\u00a0\u00bb\u00a0\u00bb][vc_column column_padding=\u00a0\u00bbno-extra-padding\u00a0\u00bb column_padding_tablet=\u00a0\u00bbinherit\u00a0\u00bb column_padding_phone=\u00a0\u00bbinherit\u00a0\u00bb column_padding_position=\u00a0\u00bball\u00a0\u00bb flex_gap_desktop=\u00a0\u00bb10px\u00a0\u00bb column_element_direction_desktop=\u00a0\u00bbdefault\u00a0\u00bb column_element_spacing=\u00a0\u00bbdefault\u00a0\u00bb desktop_text_alignment=\u00a0\u00bbdefault\u00a0\u00bb tablet_text_alignment=\u00a0\u00bbdefault\u00a0\u00bb phone_text_alignment=\u00a0\u00bbdefault\u00a0\u00bb background_color_opacity=\u00a0\u00bb1&Prime; background_hover_color_opacity=\u00a0\u00bb1&Prime; column_backdrop_filter=\u00a0\u00bbnone\u00a0\u00bb column_shadow=\u00a0\u00bbnone\u00a0\u00bb column_border_radius=\u00a0\u00bbnone\u00a0\u00bb column_link_target=\u00a0\u00bb_self\u00a0\u00bb column_position=\u00a0\u00bbdefault\u00a0\u00bb max_width_alignment_desktop=\u00a0\u00bbdefault\u00a0\u00bb max_width_alignment_tablet=\u00a0\u00bbinherit\u00a0\u00bb max_width_alignment_phone=\u00a0\u00bbinherit\u00a0\u00bb gradient_direction=\u00a0\u00bbleft_to_right\u00a0\u00bb overlay_strength=\u00a0\u00bb0.3&Prime; width=\u00a0\u00bb2\/3&Prime; tablet_width_inherit=\u00a0\u00bbdefault\u00a0\u00bb animation_type=\u00a0\u00bbdefault\u00a0\u00bb bg_image_animation=\u00a0\u00bbnone\u00a0\u00bb border_type=\u00a0\u00bbsimple\u00a0\u00bb column_border_width=\u00a0\u00bbnone\u00a0\u00bb column_border_style=\u00a0\u00bbsolid\u00a0\u00bb][vc_row_inner column_margin=\u00a0\u00bbdefault\u00a0\u00bb column_direction=\u00a0\u00bbdefault\u00a0\u00bb column_direction_tablet=\u00a0\u00bbdefault\u00a0\u00bb column_direction_phone=\u00a0\u00bbdefault\u00a0\u00bb text_align=\u00a0\u00bbleft\u00a0\u00bb row_position=\u00a0\u00bbdefault\u00a0\u00bb row_position_tablet=\u00a0\u00bbinherit\u00a0\u00bb row_position_phone=\u00a0\u00bbinherit\u00a0\u00bb overflow=\u00a0\u00bbvisible\u00a0\u00bb pointer_events=\u00a0\u00bball\u00a0\u00bb][vc_column_inner column_padding=\u00a0\u00bbno-extra-padding\u00a0\u00bb column_padding_tablet=\u00a0\u00bbinherit\u00a0\u00bb column_padding_phone=\u00a0\u00bbinherit\u00a0\u00bb column_padding_position=\u00a0\u00bball\u00a0\u00bb flex_gap_desktop=\u00a0\u00bb10px\u00a0\u00bb column_element_direction_desktop=\u00a0\u00bbdefault\u00a0\u00bb column_element_spacing=\u00a0\u00bbdefault\u00a0\u00bb desktop_text_alignment=\u00a0\u00bbdefault\u00a0\u00bb tablet_text_alignment=\u00a0\u00bbdefault\u00a0\u00bb phone_text_alignment=\u00a0\u00bbdefault\u00a0\u00bb background_color_opacity=\u00a0\u00bb1&Prime; background_hover_color_opacity=\u00a0\u00bb1&Prime; column_backdrop_filter=\u00a0\u00bbnone\u00a0\u00bb column_shadow=\u00a0\u00bbnone\u00a0\u00bb column_border_radius=\u00a0\u00bbnone\u00a0\u00bb column_link_target=\u00a0\u00bb_self\u00a0\u00bb overflow=\u00a0\u00bbvisible\u00a0\u00bb gradient_direction=\u00a0\u00bbleft_to_right\u00a0\u00bb overlay_strength=\u00a0\u00bb0.3&Prime; width=\u00a0\u00bb1\/1&Prime; tablet_width_inherit=\u00a0\u00bbdefault\u00a0\u00bb animation_type=\u00a0\u00bbdefault\u00a0\u00bb bg_image_animation=\u00a0\u00bbnone\u00a0\u00bb border_type=\u00a0\u00bbsimple\u00a0\u00bb column_border_width=\u00a0\u00bbnone\u00a0\u00bb column_border_style=\u00a0\u00bbsolid\u00a0\u00bb column_padding_type=\u00a0\u00bbdefault\u00a0\u00bb gradient_type=\u00a0\u00bbdefault\u00a0\u00bb][vc_column_text css_animation=\u00a0\u00bbfadeIn\u00a0\u00bb el_class=\u00a0\u00bbnorm\u00a0\u00bb text_direction=\u00a0\u00bbdefault\u00a0\u00bb]Cette s\u00e9rie A, codirig\u00e9e par Norrsken VC et Singular, fait suite \u00e0 une avanc\u00e9e majeure : l\u2019IA d\u2019Orakl a pr\u00e9dit de mani\u00e8re prospective les r\u00e9sultats d\u2019essais cliniques en oncologie avec une pr\u00e9cision de 90 %.[\/vc_column_text][vc_column_text text_direction=\u00a0\u00bbdefault\u00a0\u00bb]Orakl Oncology (\u00ab Orakl \u00bb), une soci\u00e9t\u00e9 TechBio qui associe l\u2019intelligence artificielle \u00e0 des donn\u00e9es biologiques issues de patients pour pr\u00e9dire les r\u00e9sultats des traitements anticanc\u00e9reux lors des essais cliniques, annonce aujourd\u2019hui une lev\u00e9e de fonds de 34 millions de dollars en s\u00e9rie A, codirig\u00e9e par Norrsken VC et Singular. Ce tour de table sursouscrit r\u00e9unit de nouveaux investisseurs, InfraVia, Serena, Bpifrance, Teampact et Plug and Play, aux c\u00f4t\u00e9s des investisseurs historiques Verve, Speedinvest et HCVC. Des business angels, parmi lesquels Thomas Wolf, Stan Polu, Jacques Boitreaud et Mostafa El Sayed, participent \u00e9galement \u00e0 cette op\u00e9ration, qui porte le total des financements lev\u00e9s par Orakl \u00e0 50 millions de dollars. Orakl b\u00e9n\u00e9ficie \u00e9galement de l\u2019accompagnement de conseillers scientifiques de premier plan, dont Philip Tagari, expert de la d\u00e9couverte et du d\u00e9veloppement de m\u00e9dicaments, qui a notamment contribu\u00e9 \u00e0 la mise sur le march\u00e9 du premier inhibiteur de KRAS chez Amgen.<\/p>\n<p>Un peu plus d\u2019un an apr\u00e8s son lancement commercial, Orakl compte 18 des 20 plus grands groupes pharmaceutiques mondiaux dans son portefeuille de prospects et transforme d\u00e9j\u00e0 ses premiers engagements avec l\u2019industrie pharmaceutique en collaborations pluriannuelles.<\/p>\n<p><strong>La biologie des patients, nouvelle fronti\u00e8re de l\u2019IA<\/strong><\/p>\n<p>L\u2019IA sait d\u00e9sormais pr\u00e9dire la structure des prot\u00e9ines et concevoir de nouvelles mol\u00e9cules. Pourtant, l\u2019un des principaux d\u00e9fis du d\u00e9veloppement de m\u00e9dicaments reste entier : pr\u00e9dire si un traitement prometteur sera r\u00e9ellement efficace chez les patients. Les traitements anticanc\u00e9reux con\u00e7us \u00e0 l\u2019aide de l\u2019IA continuent d\u2019\u00e9chouer lors des essais cliniques de phase II, en grande partie parce que la complexit\u00e9 de la biologie des patients et des tumeurs reste mal comprise.<\/p>\n<p>Orakl fait le lien entre biologie et intelligence artificielle en constituant des cohortes de patients virtuels atteints de cancer : des tumeurs issues de patients, cultiv\u00e9es en laboratoire et associ\u00e9es \u00e0 leur historique m\u00e9dical ainsi qu\u2019\u00e0 des donn\u00e9es biologiques approfondies. Ces patients virtuels permettent de tester des traitements \u00e0 grande \u00e9chelle. Orakl peut ainsi pr\u00e9dire, sur la base de donn\u00e9es \u00e9tablissant des liens de causalit\u00e9, la r\u00e9ponse d\u2019un patient \u00e0 un m\u00e9dicament plusieurs ann\u00e9es avant son entr\u00e9e en phase clinique. Les laboratoires pharmaceutiques peuvent alors s\u00e9lectionner bien plus t\u00f4t les bons m\u00e9dicaments pour les bons patients.<\/p>\n<p>Son moteur pr\u00e9dictif a d\u00e9montr\u00e9 une pr\u00e9cision de 90 % dans la pr\u00e9diction des r\u00e9sultats d\u2019essais cliniques en oncologie, avec notamment des pr\u00e9visions tr\u00e8s proches des r\u00e9sultats r\u00e9cemment observ\u00e9s lors d\u2019essais sur le cancer du pancr\u00e9as. Au-del\u00e0 de la pr\u00e9diction des crit\u00e8res d\u2019\u00e9valuation cliniques, la plateforme permet d\u2019identifier les patients les plus susceptibles de r\u00e9pondre \u00e0 un traitement et de mettre au jour les m\u00e9canismes biologiques de sensibilit\u00e9 et de r\u00e9sistance. Les cibles potentielles sont ensuite valid\u00e9es sur les mod\u00e8les propri\u00e9taires d\u2019Orakl d\u00e9riv\u00e9s de patients, selon une approche int\u00e9grant en continu l\u2019exp\u00e9rimentation en laboratoire aux mod\u00e8les d\u2019IA (\u00ab lab-in-the-loop \u00bb). Orakl constitue ainsi un portefeuille de cibles \u00e0 fort potentiel, tout en am\u00e9liorant continuellement ses mod\u00e8les d\u2019IA et en ouvrant de nouvelles perspectives pour la d\u00e9couverte de cibles th\u00e9rapeutiques.<\/p>\n<p>Gr\u00e2ce \u00e0 son r\u00e9seau hospitalier international, Orakl d\u00e9veloppe une base de donn\u00e9es propri\u00e9taire en constante expansion, qui associe donn\u00e9es biologiques des patients, informations cliniques et donn\u00e9es exp\u00e9rimentales sur la r\u00e9ponse aux m\u00e9dicaments. Des n\u00e9gociations contractuelles sont en cours avec plus de 15 centres suppl\u00e9mentaires de lutte contre le cancer en Europe, en Am\u00e9rique du Nord et en Asie, avec l\u2019ambition de constituer la base de donn\u00e9es la plus compl\u00e8te en oncologie.<\/p>\n<p><strong>Changer d\u2019\u00e9chelle : de la pr\u00e9diction \u00e0 la d\u00e9couverte de m\u00e9dicaments<\/strong><\/p>\n<ul>\n<li><strong>De nouveaux mod\u00e8les d\u2019IA<\/strong>. Orakl enrichira et approfondira sa base de donn\u00e9es et renforcera son \u00e9quipe de recherche en IA afin d\u2019\u00e9tendre ses capacit\u00e9s de pr\u00e9diction et de d\u00e9couverte en biologie du cancer.<\/li>\n<li><strong>De nouveaux types de cancer<\/strong>. La soci\u00e9t\u00e9 multipliera par cinq sa production de donn\u00e9es et \u00e9tendra ses travaux, au-del\u00e0 des cancers colorectal et du pancr\u00e9as, aux cancers du poumon non \u00e0 petites cellules (CBNPC) et de l\u2019estomac.<\/li>\n<li><strong>De nouveaux partenaires pharmaceutiques<\/strong>. De nouvelles \u00e9quipes aux \u00c9tats-Unis et au Royaume-Uni d\u00e9ploieront les pr\u00e9dictions d\u2019Orakl dans plus de dix programmes de d\u00e9veloppement de m\u00e9dicaments.<\/li>\n<li><strong>Une nouvelle capacit\u00e9<\/strong> : la d\u00e9couverte de cibles th\u00e9rapeutiques. Orakl identifiera et validera de nouvelles cibles \u00e0 viser conjointement avec d\u2019autres cibles th\u00e9rapeutiques, directement \u00e0 partir de la biologie des patients et de criblages par perturbation.<\/li>\n<\/ul>\n<p>Fond\u00e9e en 2023 et issue de Gustave Roussy, Orakl est dirig\u00e9e par la Dre Fanny Jaulin, directrice g\u00e9n\u00e9rale, le Dr Gustave Ronteix, directeur technologique, et la Dre Diane-Laure Pag\u00e8s, directrice des op\u00e9rations. Son \u00e9quipe pluridisciplinaire compte d\u00e9sormais plus de 40 personnes, dont 30 % sont titulaires d\u2019un doctorat.<\/p>\n<p><strong>La Dre Fanny Jaulin, directrice g\u00e9n\u00e9rale et cofondatrice d\u2019Orakl Oncology<\/strong>, d\u00e9clare : \u00ab <em>Depuis des d\u00e9cennies, nous d\u00e9veloppons des traitements anticanc\u00e9reux sans pouvoir pr\u00e9dire de mani\u00e8re fiable leur comportement chez les patients avant les essais cliniques. Nous sommes convaincus que la prochaine avanc\u00e9e majeure viendra de notre capacit\u00e9 \u00e0 rendre pr\u00e9visible la biologie des tumeurs et des patients. Ce financement nous permettra d\u2019\u00e9tendre les capacit\u00e9s \u00e9prouv\u00e9es d\u2019Orakl \u00e0 davantage de types de cancer et de programmes pharmaceutiques, afin d\u2019\u00e9largir notre impact en oncologie.<\/em> \u00bb<\/p>\n<p><strong>Agate Freimane, General Partner chez Norrsken VC<\/strong>, d\u00e9clare : \u00ab <em>Trop de m\u00e9dicaments entrent encore dans des essais cliniques co\u00fbteux sans que l\u2019on sache clairement chez quels patients ils seront efficaces. Orakl s\u2019attaque \u00e0 ce frein majeur avec une plateforme qui associe donn\u00e9es biologiques propri\u00e9taires, partenariats hospitaliers, infrastructures de laboratoire et IA : une combinaison particuli\u00e8rement difficile \u00e0 reproduire. Nous pensons qu\u2019Orakl a le potentiel pour devenir une plateforme de r\u00e9f\u00e9rence pour la R&amp;D en oncologie.<\/em> \u00bb<\/p>\n<p><strong>Jeremy Uzan, Partner chez Singular,<\/strong> d\u00e9clare : \u00ab <em>Fanny, Gustave et Diane-Laure r\u00e9unissent une combinaison rare d\u2019expertises en recherche sur le cancer, en biologie cellulaire et en biologie computationnelle, ainsi qu\u2019une compr\u00e9hension pr\u00e9cise des besoins de l\u2019industrie pharmaceutique. Ils ont traduit cette expertise en une plateforme qui associe donn\u00e9es biologiques issues de patients, donn\u00e9es exp\u00e9rimentales et IA pour pr\u00e9dire les r\u00e9sultats des traitements anticanc\u00e9reux lors des essais cliniques. Nous sommes fiers de continuer \u00e0 accompagner l\u2019\u00e9quipe dans cette nouvelle phase de d\u00e9veloppement.<\/em> \u00bb[\/vc_column_text][\/vc_column_inner][\/vc_row_inner][\/vc_column][vc_column column_padding=\u00a0\u00bbno-extra-padding\u00a0\u00bb column_padding_tablet=\u00a0\u00bbinherit\u00a0\u00bb column_padding_phone=\u00a0\u00bbinherit\u00a0\u00bb column_padding_position=\u00a0\u00bball\u00a0\u00bb flex_gap_desktop=\u00a0\u00bb10px\u00a0\u00bb column_element_direction_desktop=\u00a0\u00bbdefault\u00a0\u00bb column_element_spacing=\u00a0\u00bbdefault\u00a0\u00bb desktop_text_alignment=\u00a0\u00bbdefault\u00a0\u00bb tablet_text_alignment=\u00a0\u00bbdefault\u00a0\u00bb phone_text_alignment=\u00a0\u00bbdefault\u00a0\u00bb background_color_opacity=\u00a0\u00bb1&Prime; background_hover_color_opacity=\u00a0\u00bb1&Prime; column_backdrop_filter=\u00a0\u00bbnone\u00a0\u00bb column_shadow=\u00a0\u00bbnone\u00a0\u00bb column_border_radius=\u00a0\u00bbnone\u00a0\u00bb column_link_target=\u00a0\u00bb_self\u00a0\u00bb column_position=\u00a0\u00bbdefault\u00a0\u00bb max_width_alignment_desktop=\u00a0\u00bbdefault\u00a0\u00bb max_width_alignment_tablet=\u00a0\u00bbinherit\u00a0\u00bb max_width_alignment_phone=\u00a0\u00bbinherit\u00a0\u00bb gradient_direction=\u00a0\u00bbleft_to_right\u00a0\u00bb overlay_strength=\u00a0\u00bb0.3&Prime; width=\u00a0\u00bb1\/3&Prime; tablet_width_inherit=\u00a0\u00bbdefault\u00a0\u00bb animation_type=\u00a0\u00bbdefault\u00a0\u00bb bg_image_animation=\u00a0\u00bbnone\u00a0\u00bb border_type=\u00a0\u00bbsimple\u00a0\u00bb column_border_width=\u00a0\u00bbnone\u00a0\u00bb column_border_style=\u00a0\u00bbsolid\u00a0\u00bb][nectar_btn size=\u00a0\u00bblarge\u00a0\u00bb open_new_tab=\u00a0\u00bbtrue\u00a0\u00bb button_style=\u00a0\u00bbregular\u00a0\u00bb button_color_2=\u00a0\u00bbAccent-Color\u00a0\u00bb icon_family=\u00a0\u00bbnone\u00a0\u00bb text=\u00a0\u00bbVERSION PDF\u00a0\u00bb url=\u00a0\u00bb\/wp-content\/uploads\/2026\/11\/CP-Orakl-Nov-2026.docx.pdf\u00a0\u00bb css_animation=\u00a0\u00bbnone\u00a0\u00bb][divider line_type=\u00a0\u00bbFull Width Line\u00a0\u00bb line_thickness=\u00a0\u00bb1&Prime; divider_color=\u00a0\u00bbextra-color-2&Prime; animate=\u00a0\u00bbyes\u00a0\u00bb custom_height=\u00a0\u00bb50&Prime; delay=\u00a0\u00bb450&Prime;][vc_column_text el_class=\u00a0\u00bbbeige\u00a0\u00bb text_direction=\u00a0\u00bbdefault\u00a0\u00bb]CONTACTS PRESSE[\/vc_column_text][vc_column_text el_class=\u00a0\u00bbsmall\u00a0\u00bb text_direction=\u00a0\u00bbdefault\u00a0\u00bb]<strong>InfraVia<\/strong><br \/>\nAntoine Denry | TADDEO<br \/>\n<a href=\"mailto:antoine.denry@taddeo.fr\">antoine.denry@taddeo.fr<\/a><br \/>\n+33 (0) 6 18 07 83 27<\/p>\n<p><span style=\"font-weight: 400;\">Cl\u00e9mence Midi\u00e8re | Taddeo<br \/>\n<\/span><span style=\"font-weight: 400;\"><a href=\"mailto:clemence.midiere@taddeo.fr\">clemence.midiere@taddeo.fr<\/a><br \/>\n<\/span><span style=\"font-weight: 400;\">+33 (0) 6 46 76 70 22<\/span><\/p>\n<p><span style=\"font-weight: 400;\">Gwena\u00eblle Boucly<br \/>\nDirectrice Communication InfraVia<br \/>\n<\/span><a href=\"mailto:gboucly@infraviacapital.com\"><span style=\"font-weight: 400;\">gboucly@infraviacapital.com<\/span><\/a><span style=\"font-weight: 400;\"><br \/>\n+33 (0) 6 80 57 33<\/span>[\/vc_column_text][\/vc_column][\/vc_row][vc_row type=\u00a0\u00bbin_container\u00a0\u00bb full_screen_row_position=\u00a0\u00bbmiddle\u00a0\u00bb column_margin=\u00a0\u00bbdefault\u00a0\u00bb column_direction=\u00a0\u00bbdefault\u00a0\u00bb column_direction_tablet=\u00a0\u00bbdefault\u00a0\u00bb column_direction_phone=\u00a0\u00bbdefault\u00a0\u00bb scene_position=\u00a0\u00bbcenter\u00a0\u00bb top_padding=\u00a0\u00bb50px\u00a0\u00bb text_color=\u00a0\u00bbdark\u00a0\u00bb text_align=\u00a0\u00bbleft\u00a0\u00bb row_border_radius=\u00a0\u00bbnone\u00a0\u00bb row_border_radius_applies=\u00a0\u00bbbg\u00a0\u00bb row_position_desktop=\u00a0\u00bbdefault\u00a0\u00bb row_position_tablet=\u00a0\u00bbinherit\u00a0\u00bb row_position_phone=\u00a0\u00bbinherit\u00a0\u00bb overflow=\u00a0\u00bbvisible\u00a0\u00bb overlay_strength=\u00a0\u00bb0.3&Prime; gradient_direction=\u00a0\u00bbleft_to_right\u00a0\u00bb shape_divider_position=\u00a0\u00bbbottom\u00a0\u00bb bg_image_animation=\u00a0\u00bbnone\u00a0\u00bb shape_type=\u00a0\u00bb\u00a0\u00bb][vc_column column_padding=\u00a0\u00bbno-extra-padding\u00a0\u00bb column_padding_tablet=\u00a0\u00bbinherit\u00a0\u00bb column_padding_phone=\u00a0\u00bbinherit\u00a0\u00bb column_padding_position=\u00a0\u00bball\u00a0\u00bb flex_gap_desktop=\u00a0\u00bb10px\u00a0\u00bb column_element_direction_desktop=\u00a0\u00bbdefault\u00a0\u00bb column_element_spacing=\u00a0\u00bbdefault\u00a0\u00bb desktop_text_alignment=\u00a0\u00bbdefault\u00a0\u00bb tablet_text_alignment=\u00a0\u00bbdefault\u00a0\u00bb phone_text_alignment=\u00a0\u00bbdefault\u00a0\u00bb background_color_opacity=\u00a0\u00bb1&Prime; background_hover_color_opacity=\u00a0\u00bb1&Prime; column_backdrop_filter=\u00a0\u00bbnone\u00a0\u00bb column_shadow=\u00a0\u00bbnone\u00a0\u00bb column_border_radius=\u00a0\u00bbnone\u00a0\u00bb column_link_target=\u00a0\u00bb_self\u00a0\u00bb column_position=\u00a0\u00bbdefault\u00a0\u00bb max_width_alignment_desktop=\u00a0\u00bbdefault\u00a0\u00bb max_width_alignment_tablet=\u00a0\u00bbinherit\u00a0\u00bb max_width_alignment_phone=\u00a0\u00bbinherit\u00a0\u00bb gradient_direction=\u00a0\u00bbleft_to_right\u00a0\u00bb overlay_strength=\u00a0\u00bb0.3&Prime; width=\u00a0\u00bb1\/1&Prime; tablet_width_inherit=\u00a0\u00bbdefault\u00a0\u00bb animation_type=\u00a0\u00bbdefault\u00a0\u00bb bg_image_animation=\u00a0\u00bbnone\u00a0\u00bb border_type=\u00a0\u00bbsimple\u00a0\u00bb column_border_width=\u00a0\u00bbnone\u00a0\u00bb column_border_style=\u00a0\u00bbsolid\u00a0\u00bb][vc_row_inner column_margin=\u00a0\u00bbdefault\u00a0\u00bb column_direction=\u00a0\u00bbdefault\u00a0\u00bb column_direction_tablet=\u00a0\u00bbdefault\u00a0\u00bb column_direction_phone=\u00a0\u00bbdefault\u00a0\u00bb text_align=\u00a0\u00bbleft\u00a0\u00bb row_position=\u00a0\u00bbdefault\u00a0\u00bb row_position_tablet=\u00a0\u00bbinherit\u00a0\u00bb row_position_phone=\u00a0\u00bbinherit\u00a0\u00bb overflow=\u00a0\u00bbvisible\u00a0\u00bb pointer_events=\u00a0\u00bball\u00a0\u00bb][vc_column_inner column_padding=\u00a0\u00bbno-extra-padding\u00a0\u00bb column_padding_tablet=\u00a0\u00bbinherit\u00a0\u00bb column_padding_phone=\u00a0\u00bbinherit\u00a0\u00bb column_padding_position=\u00a0\u00bball\u00a0\u00bb flex_gap_desktop=\u00a0\u00bb10px\u00a0\u00bb column_element_direction_desktop=\u00a0\u00bbdefault\u00a0\u00bb column_element_spacing=\u00a0\u00bbdefault\u00a0\u00bb desktop_text_alignment=\u00a0\u00bbdefault\u00a0\u00bb tablet_text_alignment=\u00a0\u00bbdefault\u00a0\u00bb phone_text_alignment=\u00a0\u00bbdefault\u00a0\u00bb background_color_opacity=\u00a0\u00bb1&Prime; background_hover_color_opacity=\u00a0\u00bb1&Prime; column_backdrop_filter=\u00a0\u00bbnone\u00a0\u00bb column_shadow=\u00a0\u00bbnone\u00a0\u00bb column_border_radius=\u00a0\u00bbnone\u00a0\u00bb column_link_target=\u00a0\u00bb_self\u00a0\u00bb overflow=\u00a0\u00bbvisible\u00a0\u00bb gradient_direction=\u00a0\u00bbleft_to_right\u00a0\u00bb overlay_strength=\u00a0\u00bb0.3&Prime; width=\u00a0\u00bb2\/3&Prime; tablet_width_inherit=\u00a0\u00bbdefault\u00a0\u00bb animation_type=\u00a0\u00bbdefault\u00a0\u00bb bg_image_animation=\u00a0\u00bbnone\u00a0\u00bb border_type=\u00a0\u00bbsimple\u00a0\u00bb column_border_width=\u00a0\u00bbnone\u00a0\u00bb column_border_style=\u00a0\u00bbsolid\u00a0\u00bb][divider line_type=\u00a0\u00bbSmall Line\u00a0\u00bb line_alignment=\u00a0\u00bbdefault\u00a0\u00bb line_thickness=\u00a0\u00bb1&Prime; divider_color=\u00a0\u00bbextra-color-2&Prime; animate=\u00a0\u00bbyes\u00a0\u00bb custom_height=\u00a0\u00bb50&Prime; custom_line_width=\u00a0\u00bb250&Prime; delay=\u00a0\u00bb550&Prime;][nectar_cta btn_style=\u00a0\u00bbunderline\u00a0\u00bb underline_visibility=\u00a0\u00bbdefault\u00a0\u00bb heading_tag=\u00a0\u00bbh3&Prime; link_type=\u00a0\u00bbregular\u00a0\u00bb button_color=\u00a0\u00bbdefault\u00a0\u00bb text_color=\u00a0\u00bb#031a3b\u00a0\u00bb button_border_thickness=\u00a0\u00bb0px\u00a0\u00bb alignment=\u00a0\u00bbleft\u00a0\u00bb alignment_tablet=\u00a0\u00bbdefault\u00a0\u00bb alignment_phone=\u00a0\u00bbdefault\u00a0\u00bb display=\u00a0\u00bbblock\u00a0\u00bb display_tablet=\u00a0\u00bbinherit\u00a0\u00bb display_phone=\u00a0\u00bbinherit\u00a0\u00bb icon_family=\u00a0\u00bbnone\u00a0\u00bb icon_alignment=\u00a0\u00bbleft\u00a0\u00bb text=\u00a0\u00bb&lt;\u00a0\u00bb link_text=\u00a0\u00bbRETOUR AUX ACTUALIT\u00c9S\u00a0\u00bb url=\u00a0\u00bb\/fr\/actualites\/\u00a0\u00bb][\/vc_column_inner][vc_column_inner column_padding=\u00a0\u00bbno-extra-padding\u00a0\u00bb column_padding_tablet=\u00a0\u00bbinherit\u00a0\u00bb column_padding_phone=\u00a0\u00bbinherit\u00a0\u00bb column_padding_position=\u00a0\u00bball\u00a0\u00bb flex_gap_desktop=\u00a0\u00bb10px\u00a0\u00bb column_element_direction_desktop=\u00a0\u00bbdefault\u00a0\u00bb column_element_spacing=\u00a0\u00bbdefault\u00a0\u00bb desktop_text_alignment=\u00a0\u00bbdefault\u00a0\u00bb tablet_text_alignment=\u00a0\u00bbdefault\u00a0\u00bb phone_text_alignment=\u00a0\u00bbdefault\u00a0\u00bb background_color_opacity=\u00a0\u00bb1&Prime; background_hover_color_opacity=\u00a0\u00bb1&Prime; column_backdrop_filter=\u00a0\u00bbnone\u00a0\u00bb column_shadow=\u00a0\u00bbnone\u00a0\u00bb column_border_radius=\u00a0\u00bbnone\u00a0\u00bb column_link_target=\u00a0\u00bb_self\u00a0\u00bb overflow=\u00a0\u00bbvisible\u00a0\u00bb gradient_direction=\u00a0\u00bbleft_to_right\u00a0\u00bb overlay_strength=\u00a0\u00bb0.3&Prime; width=\u00a0\u00bb1\/3&Prime; tablet_width_inherit=\u00a0\u00bbdefault\u00a0\u00bb animation_type=\u00a0\u00bbdefault\u00a0\u00bb bg_image_animation=\u00a0\u00bbnone\u00a0\u00bb border_type=\u00a0\u00bbsimple\u00a0\u00bb column_border_width=\u00a0\u00bbnone\u00a0\u00bb column_border_style=\u00a0\u00bbsolid\u00a0\u00bb][\/vc_column_inner][\/vc_row_inner][\/vc_column][\/vc_row]\n","protected":false},"excerpt":{"rendered":"<p>The Series A, co-led by Norrsken VC and Singular, follows a breakthrough: Orakl&rsquo;s AI predicted cancer clinical trial outcomes prospectively with 90% accuracy.<\/p>\n","protected":false},"author":5,"featured_media":20715,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"inline_featured_image":false,"footnotes":""},"categories":[112,43,108],"tags":[],"class_list":["post-20719","post","type-post","status-publish","format-standard","has-post-thumbnail","category-toutes-actus","category-general-fr","category-growth-fr"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.8 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>InfraVia Growth investi dans Orakl Oncology pour pr\u00e9dire la r\u00e9ponse aux traitements anticanc\u00e9reux avant les essais cliniques - InfraVia<\/title>\n<meta name=\"description\" content=\"Cette s\u00e9rie A, codirig\u00e9e par Norrsken VC et Singular, fait suite \u00e0 une avanc\u00e9e majeure : l\u2019IA d\u2019Orakl a pr\u00e9dit de mani\u00e8re prospective les r\u00e9sultats d\u2019essais cliniques en oncologie avec une pr\u00e9cision de 90 %.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/infraviacapital.com\/infravia-growth-invests-in-orakl-oncology-to-make-cancer-drug-response-predictable-before-clinical-trials\/\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"InfraVia Growth investi dans Orakl Oncology pour pr\u00e9dire la r\u00e9ponse aux traitements anticanc\u00e9reux avant les essais cliniques\" \/>\n<meta property=\"og:description\" content=\"Cette s\u00e9rie A, codirig\u00e9e par Norrsken VC et Singular, fait suite \u00e0 une avanc\u00e9e majeure : l\u2019IA d\u2019Orakl a pr\u00e9dit de mani\u00e8re prospective les r\u00e9sultats d\u2019essais cliniques en oncologie avec une pr\u00e9cision de 90 %.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/infraviacapital.com\/infravia-growth-invests-in-orakl-oncology-to-make-cancer-drug-response-predictable-before-clinical-trials\/\" \/>\n<meta property=\"og:site_name\" content=\"InfraVia\" \/>\n<meta property=\"article:published_time\" content=\"2026-11-12T09:00:44+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/infraviacapital.com\/wp-content\/uploads\/2026\/11\/orakl-vignette-logo.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"512\" \/>\n\t<meta property=\"og:image:height\" content=\"384\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"WeAreBlow\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"\u00c9crit par\" \/>\n\t<meta name=\"twitter:data1\" content=\"WeAreBlow\" \/>\n\t<meta name=\"twitter:label2\" content=\"Dur\u00e9e de lecture estim\u00e9e\" \/>\n\t<meta name=\"twitter:data2\" content=\"16 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/infraviacapital.com\\\/infravia-growth-invests-in-orakl-oncology-to-make-cancer-drug-response-predictable-before-clinical-trials\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/infraviacapital.com\\\/infravia-growth-invests-in-orakl-oncology-to-make-cancer-drug-response-predictable-before-clinical-trials\\\/\"},\"author\":{\"name\":\"WeAreBlow\",\"@id\":\"https:\\\/\\\/infraviacapital.com\\\/#\\\/schema\\\/person\\\/dd5b388ef02863da2d030ecdda32586c\"},\"headline\":\"InfraVia Growth investi dans Orakl Oncology pour pr\u00e9dire la r\u00e9ponse aux traitements anticanc\u00e9reux avant les essais cliniques\",\"datePublished\":\"2026-11-12T09:00:44+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/infraviacapital.com\\\/infravia-growth-invests-in-orakl-oncology-to-make-cancer-drug-response-predictable-before-clinical-trials\\\/\"},\"wordCount\":3279,\"publisher\":{\"@id\":\"https:\\\/\\\/infraviacapital.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/infraviacapital.com\\\/infravia-growth-invests-in-orakl-oncology-to-make-cancer-drug-response-predictable-before-clinical-trials\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/infraviacapital.com\\\/wp-content\\\/uploads\\\/2026\\\/11\\\/orakl-vgnette.jpg\",\"articleSection\":[\"Toutes\",\"Presse\",\"Growth\"],\"inLanguage\":\"fr-FR\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/infraviacapital.com\\\/infravia-growth-invests-in-orakl-oncology-to-make-cancer-drug-response-predictable-before-clinical-trials\\\/\",\"url\":\"https:\\\/\\\/infraviacapital.com\\\/infravia-growth-invests-in-orakl-oncology-to-make-cancer-drug-response-predictable-before-clinical-trials\\\/\",\"name\":\"InfraVia Growth investi dans Orakl Oncology pour pr\u00e9dire la r\u00e9ponse aux traitements anticanc\u00e9reux avant les essais cliniques - InfraVia\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/infraviacapital.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/infraviacapital.com\\\/infravia-growth-invests-in-orakl-oncology-to-make-cancer-drug-response-predictable-before-clinical-trials\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/infraviacapital.com\\\/infravia-growth-invests-in-orakl-oncology-to-make-cancer-drug-response-predictable-before-clinical-trials\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/infraviacapital.com\\\/wp-content\\\/uploads\\\/2026\\\/11\\\/orakl-vgnette.jpg\",\"datePublished\":\"2026-11-12T09:00:44+00:00\",\"description\":\"Cette s\u00e9rie A, codirig\u00e9e par Norrsken VC et Singular, fait suite \u00e0 une avanc\u00e9e majeure : l\u2019IA d\u2019Orakl a pr\u00e9dit de mani\u00e8re prospective les r\u00e9sultats d\u2019essais cliniques en oncologie avec une pr\u00e9cision de 90 %.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/infraviacapital.com\\\/infravia-growth-invests-in-orakl-oncology-to-make-cancer-drug-response-predictable-before-clinical-trials\\\/#breadcrumb\"},\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/infraviacapital.com\\\/infravia-growth-invests-in-orakl-oncology-to-make-cancer-drug-response-predictable-before-clinical-trials\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\\\/\\\/infraviacapital.com\\\/infravia-growth-invests-in-orakl-oncology-to-make-cancer-drug-response-predictable-before-clinical-trials\\\/#primaryimage\",\"url\":\"https:\\\/\\\/infraviacapital.com\\\/wp-content\\\/uploads\\\/2026\\\/11\\\/orakl-vgnette.jpg\",\"contentUrl\":\"https:\\\/\\\/infraviacapital.com\\\/wp-content\\\/uploads\\\/2026\\\/11\\\/orakl-vgnette.jpg\",\"width\":512,\"height\":384},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/infraviacapital.com\\\/infravia-growth-invests-in-orakl-oncology-to-make-cancer-drug-response-predictable-before-clinical-trials\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/infraviacapital.com\\\/fr\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"InfraVia Growth investi dans Orakl Oncology pour pr\u00e9dire la r\u00e9ponse aux traitements anticanc\u00e9reux avant les essais cliniques\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/infraviacapital.com\\\/#website\",\"url\":\"https:\\\/\\\/infraviacapital.com\\\/\",\"name\":\"Infravia Capital\",\"description\":\"We connect, we power, we growth\",\"publisher\":{\"@id\":\"https:\\\/\\\/infraviacapital.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/infraviacapital.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"fr-FR\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/infraviacapital.com\\\/#organization\",\"name\":\"Infravia Capital\",\"url\":\"https:\\\/\\\/infraviacapital.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\\\/\\\/infraviacapital.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/infraviacapital.com\\\/wp-content\\\/uploads\\\/2021\\\/09\\\/maj-logoblue.svg\",\"contentUrl\":\"https:\\\/\\\/infraviacapital.com\\\/wp-content\\\/uploads\\\/2021\\\/09\\\/maj-logoblue.svg\",\"width\":\"1024\",\"height\":\"1024\",\"caption\":\"Infravia Capital\"},\"image\":{\"@id\":\"https:\\\/\\\/infraviacapital.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/infraviacapital.com\\\/#\\\/schema\\\/person\\\/dd5b388ef02863da2d030ecdda32586c\",\"name\":\"WeAreBlow\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/4fe45c4c426fb5aa4064d00ab9add0ae2ca6ed3b17aeb23f05d9f8cd81f0f6c8?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/4fe45c4c426fb5aa4064d00ab9add0ae2ca6ed3b17aeb23f05d9f8cd81f0f6c8?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/4fe45c4c426fb5aa4064d00ab9add0ae2ca6ed3b17aeb23f05d9f8cd81f0f6c8?s=96&d=mm&r=g\",\"caption\":\"WeAreBlow\"},\"sameAs\":[\"https:\\\/\\\/infraviacapital.com\"]}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"InfraVia Growth investi dans Orakl Oncology pour pr\u00e9dire la r\u00e9ponse aux traitements anticanc\u00e9reux avant les essais cliniques - InfraVia","description":"Cette s\u00e9rie A, codirig\u00e9e par Norrsken VC et Singular, fait suite \u00e0 une avanc\u00e9e majeure : l\u2019IA d\u2019Orakl a pr\u00e9dit de mani\u00e8re prospective les r\u00e9sultats d\u2019essais cliniques en oncologie avec une pr\u00e9cision de 90 %.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/infraviacapital.com\/infravia-growth-invests-in-orakl-oncology-to-make-cancer-drug-response-predictable-before-clinical-trials\/","og_locale":"fr_FR","og_type":"article","og_title":"InfraVia Growth investi dans Orakl Oncology pour pr\u00e9dire la r\u00e9ponse aux traitements anticanc\u00e9reux avant les essais cliniques","og_description":"Cette s\u00e9rie A, codirig\u00e9e par Norrsken VC et Singular, fait suite \u00e0 une avanc\u00e9e majeure : l\u2019IA d\u2019Orakl a pr\u00e9dit de mani\u00e8re prospective les r\u00e9sultats d\u2019essais cliniques en oncologie avec une pr\u00e9cision de 90 %.","og_url":"https:\/\/infraviacapital.com\/infravia-growth-invests-in-orakl-oncology-to-make-cancer-drug-response-predictable-before-clinical-trials\/","og_site_name":"InfraVia","article_published_time":"2026-11-12T09:00:44+00:00","og_image":[{"width":512,"height":384,"url":"https:\/\/infraviacapital.com\/wp-content\/uploads\/2026\/11\/orakl-vignette-logo.jpg","type":"image\/jpeg"}],"author":"WeAreBlow","twitter_card":"summary_large_image","twitter_misc":{"\u00c9crit par":"WeAreBlow","Dur\u00e9e de lecture estim\u00e9e":"16 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/infraviacapital.com\/infravia-growth-invests-in-orakl-oncology-to-make-cancer-drug-response-predictable-before-clinical-trials\/#article","isPartOf":{"@id":"https:\/\/infraviacapital.com\/infravia-growth-invests-in-orakl-oncology-to-make-cancer-drug-response-predictable-before-clinical-trials\/"},"author":{"name":"WeAreBlow","@id":"https:\/\/infraviacapital.com\/#\/schema\/person\/dd5b388ef02863da2d030ecdda32586c"},"headline":"InfraVia Growth investi dans Orakl Oncology pour pr\u00e9dire la r\u00e9ponse aux traitements anticanc\u00e9reux avant les essais cliniques","datePublished":"2026-11-12T09:00:44+00:00","mainEntityOfPage":{"@id":"https:\/\/infraviacapital.com\/infravia-growth-invests-in-orakl-oncology-to-make-cancer-drug-response-predictable-before-clinical-trials\/"},"wordCount":3279,"publisher":{"@id":"https:\/\/infraviacapital.com\/#organization"},"image":{"@id":"https:\/\/infraviacapital.com\/infravia-growth-invests-in-orakl-oncology-to-make-cancer-drug-response-predictable-before-clinical-trials\/#primaryimage"},"thumbnailUrl":"https:\/\/infraviacapital.com\/wp-content\/uploads\/2026\/11\/orakl-vgnette.jpg","articleSection":["Toutes","Presse","Growth"],"inLanguage":"fr-FR"},{"@type":"WebPage","@id":"https:\/\/infraviacapital.com\/infravia-growth-invests-in-orakl-oncology-to-make-cancer-drug-response-predictable-before-clinical-trials\/","url":"https:\/\/infraviacapital.com\/infravia-growth-invests-in-orakl-oncology-to-make-cancer-drug-response-predictable-before-clinical-trials\/","name":"InfraVia Growth investi dans Orakl Oncology pour pr\u00e9dire la r\u00e9ponse aux traitements anticanc\u00e9reux avant les essais cliniques - InfraVia","isPartOf":{"@id":"https:\/\/infraviacapital.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/infraviacapital.com\/infravia-growth-invests-in-orakl-oncology-to-make-cancer-drug-response-predictable-before-clinical-trials\/#primaryimage"},"image":{"@id":"https:\/\/infraviacapital.com\/infravia-growth-invests-in-orakl-oncology-to-make-cancer-drug-response-predictable-before-clinical-trials\/#primaryimage"},"thumbnailUrl":"https:\/\/infraviacapital.com\/wp-content\/uploads\/2026\/11\/orakl-vgnette.jpg","datePublished":"2026-11-12T09:00:44+00:00","description":"Cette s\u00e9rie A, codirig\u00e9e par Norrsken VC et Singular, fait suite \u00e0 une avanc\u00e9e majeure : l\u2019IA d\u2019Orakl a pr\u00e9dit de mani\u00e8re prospective les r\u00e9sultats d\u2019essais cliniques en oncologie avec une pr\u00e9cision de 90 %.","breadcrumb":{"@id":"https:\/\/infraviacapital.com\/infravia-growth-invests-in-orakl-oncology-to-make-cancer-drug-response-predictable-before-clinical-trials\/#breadcrumb"},"inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/infraviacapital.com\/infravia-growth-invests-in-orakl-oncology-to-make-cancer-drug-response-predictable-before-clinical-trials\/"]}]},{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/infraviacapital.com\/infravia-growth-invests-in-orakl-oncology-to-make-cancer-drug-response-predictable-before-clinical-trials\/#primaryimage","url":"https:\/\/infraviacapital.com\/wp-content\/uploads\/2026\/11\/orakl-vgnette.jpg","contentUrl":"https:\/\/infraviacapital.com\/wp-content\/uploads\/2026\/11\/orakl-vgnette.jpg","width":512,"height":384},{"@type":"BreadcrumbList","@id":"https:\/\/infraviacapital.com\/infravia-growth-invests-in-orakl-oncology-to-make-cancer-drug-response-predictable-before-clinical-trials\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/infraviacapital.com\/fr\/"},{"@type":"ListItem","position":2,"name":"InfraVia Growth investi dans Orakl Oncology pour pr\u00e9dire la r\u00e9ponse aux traitements anticanc\u00e9reux avant les essais cliniques"}]},{"@type":"WebSite","@id":"https:\/\/infraviacapital.com\/#website","url":"https:\/\/infraviacapital.com\/","name":"Infravia Capital","description":"We connect, we power, we growth","publisher":{"@id":"https:\/\/infraviacapital.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/infraviacapital.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"fr-FR"},{"@type":"Organization","@id":"https:\/\/infraviacapital.com\/#organization","name":"Infravia Capital","url":"https:\/\/infraviacapital.com\/","logo":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/infraviacapital.com\/#\/schema\/logo\/image\/","url":"https:\/\/infraviacapital.com\/wp-content\/uploads\/2021\/09\/maj-logoblue.svg","contentUrl":"https:\/\/infraviacapital.com\/wp-content\/uploads\/2021\/09\/maj-logoblue.svg","width":"1024","height":"1024","caption":"Infravia Capital"},"image":{"@id":"https:\/\/infraviacapital.com\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/infraviacapital.com\/#\/schema\/person\/dd5b388ef02863da2d030ecdda32586c","name":"WeAreBlow","image":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/secure.gravatar.com\/avatar\/4fe45c4c426fb5aa4064d00ab9add0ae2ca6ed3b17aeb23f05d9f8cd81f0f6c8?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/4fe45c4c426fb5aa4064d00ab9add0ae2ca6ed3b17aeb23f05d9f8cd81f0f6c8?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/4fe45c4c426fb5aa4064d00ab9add0ae2ca6ed3b17aeb23f05d9f8cd81f0f6c8?s=96&d=mm&r=g","caption":"WeAreBlow"},"sameAs":["https:\/\/infraviacapital.com"]}]}},"_links":{"self":[{"href":"https:\/\/infraviacapital.com\/fr\/wp-json\/wp\/v2\/posts\/20719","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/infraviacapital.com\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/infraviacapital.com\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/infraviacapital.com\/fr\/wp-json\/wp\/v2\/users\/5"}],"replies":[{"embeddable":true,"href":"https:\/\/infraviacapital.com\/fr\/wp-json\/wp\/v2\/comments?post=20719"}],"version-history":[{"count":4,"href":"https:\/\/infraviacapital.com\/fr\/wp-json\/wp\/v2\/posts\/20719\/revisions"}],"predecessor-version":[{"id":20725,"href":"https:\/\/infraviacapital.com\/fr\/wp-json\/wp\/v2\/posts\/20719\/revisions\/20725"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/infraviacapital.com\/fr\/wp-json\/wp\/v2\/media\/20715"}],"wp:attachment":[{"href":"https:\/\/infraviacapital.com\/fr\/wp-json\/wp\/v2\/media?parent=20719"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/infraviacapital.com\/fr\/wp-json\/wp\/v2\/categories?post=20719"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/infraviacapital.com\/fr\/wp-json\/wp\/v2\/tags?post=20719"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}